What is the XALute Study?

The XALute Study is a clinical study (also known as a clinical trial or clinical research study) being done to learn more about an investigational immunotherapy cancer drug called Xaluritamig.

This study is for people with metastatic castration-resistant prostate cancer (mCRPC). One of the main research questions is: Will Xaluritamig help people with mCRPC live longer compared to those using existing treatment options?

Xaluritamig is being developed for advanced prostate cancer. Xaluritamig is designed to activate the immune system against prostate cancer cells. Xaluritamig has not been approved by health authorities for any use in any country. It can only be given to participants in a clinical study.

Who can participate?

These are some of the requirements to be part of the study. The study doctor will discuss the full list of requirements with you to see if you are eligible for the study.

Age

Adults 18+ years of age

Diagnosis

Metastatic castration-resistant prostate cancer (mCRPC)

Past treatment

At least 1 prior novel hormonal therapy (enzalutamide, abiraterone, apalutamide, or darolutamide)

No more than 1 course of taxane chemotherapy

Abilities

Generally able to walk, care for self, and do light work

Why should I participate?

  • In this study, you will receive either an approved prostate cancer treatment or an investigational study drug which is in development for treating advanced prostate cancer.
  • There is a possibility that your condition may get better, but it could stay the same or even get worse. No one knows if taking part in this study will help you.
  • By being part of this study, your unique cancer treatment journey becomes part of the groundwork that may help to improve treatment for future patients.
  • If you are Black/African American, Latino/Hispanic, Asian American, Native Hawaiian or Other Pacific Islander, or American Indian/Alaska Native, your participation helps to make sure diverse experiences are represented in important prostate cancer research.